Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy

Leukemia Research

Volumn 32, Issue 7, 2008, Pages 1085-1090

  Corso, A ^a   Mangiacavalli, S ^a   Barbarano, L ^b   Montalbetti, L ^c   Mazzone, A ^d   Fava, S ^d   Varettoni, M ^a   Zappasodi, P ^a   Morra, E ^b   Lazzarino, M ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c Divisione di Malattie Infettive   (Italy)

^d Ospedale di Legnano   (Italy)

Author keywords

High dose therapy; Intensification; Multiple myeloma; Thalidomide; Up front therapy

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRADYCARDIA; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SEDATION; SIDE EFFECT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; TREATMENT OUTCOME;

EID: 41949136010     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.11.011     Document Type: Article

References (34)

1. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 335 (1996) 91-97
2. Child J.A., Gareth J.M., Davies F.E., Owen R.G., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New Engl J Med 348 (2003) 1875-1883
3. Alexanian R., Weber D., Giralt S., et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transpl 27 (2001) 1037-1043
4. Lahuerta J.J., Martinez-Lopez J.-L., Serna J.D., et al. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma pts. Br J Haematol 109 (2000) 438-446
5. Davies F.E., Forsyth P.D., Rawstron A.C., et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 112 (2001) 814-819
6. Barlogie B., Jagannath S., Vesole, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89 (1997) 789-793
7. Barlogie B., Tricot G., van Rhee F., et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135 (2006) 158-164
8. Shaughnessy J., Tian E., Sawyer J., et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 120 (2003) 44-52
9. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. New Engl J Med 341 (1999) 1565-1571
10. Cavenagh J.D., and Oakervee H. Thalidomide in multiple myeloma: current status and future prospect. Br J Haematol 120 (2003) 18-26
11. Dimopoulos M.A., Agnostopuolos A., and Weber D. Treatment of plasma cells dyscrasia with thalidomide and its derivates. J Clin Oncol 21 (2003) 4444-4452
12. Barlogie B., Desikan R., Eddlemon P., et al. Extended survival in advance and refractory multiple myeloma after single agent thalidomide Identification of prognostic factors in a Phase II study of 169 patients. Blood 98 (2001) 492-495
13. Yakoub-Agha I., Attal M., Dumonet C., et al. Thalidomide in patients with advance multiple myeloma: a study of 83 patients report of the intergroup Froncophone du Myelome (IFM). Hematol J 3 (2002) 185-192
14. Agnostopoulos A., Weber D., Rankin R., et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121 (2003) 768-771
15. Dimopoulos M.A., Zervas K., Kouvatseas G., et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12 (2001) 991-995
16. Palumbo A., Giaccone L., Bertola A., et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86 (2001) 399-403
17. Palumbo A., Bertola A., Falco P., et al. Efficacy of low-dose thalidomide as first salvage regimen in multiple myeloma. Hematol J 5 (2004) 318-324
18. Palumbo A., Falco P., Ambrosini M.T., et al. Thalidomide plus dexamethasone is an effective salvage regimen for patients relapsing after autologous transplantation. Eur J Haematol 75 (2005) 391-395
19. Rajkumar S.V., Hayman S., Gertz M.A., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20 (2002) 4319-4323
20. Weber D., Rankin K., Gavino M., Delasalle K., and Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21 (2003) 16-19
21. Cavo M., Zamagni E., Tosi P., et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89 (2004) 826-831
22. Cavo M., Zamagni E., Tosi P., et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 (2005) 35-39
23. Barlogie B., Tricot G., Anaissie E., et al. Thalidomide and hemopoietic-cell transplantation for multiple myeloma. New Engl J Med 354 (2006) 1021-1030
24. Durie B.G., Harousseau J.L., Miquel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 20 (2006) 1467-1473
25. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. http:ctep.cancer.gov. Accessed December 12, 2003.
26. Rajkumar V., Blood E., Vesole D., et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
27. Zervas K., Dimopoulos M.A., Hatzicharissi E., et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 15 (2004) 134-138
28. Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood 106 (2005) 4050-4056
29. Oakervee H.E., Pollat R., Curry N., et al. PAD combination therapy (PS341, doxorubicin and dexamethasone) for untreated multiple myeloma. Br J Haematol 129 (2005) 755-762
30. Jagannath S., Durie B., Wolf J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129 (2005) 776-783
31. Harousseau J.L., Attal M., Leleu X., et al. Bortezomib plus fexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91 (2006) 1501-1507
32. Macro M., Divine M., Uzunhan Y., et al. Dexamethasone + thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. Blood 108 (2006) 57 [abstr]
33. Kumar S., Lacy M., Dispensieri A., et al. Analysis of outcome after autologous stem transplantation in patients with newly diagnosed myeloma: comparison of different induction regimens. Blood 108 (2006) 3079 [abstr]
34. Attal M., Harousseau J.L., Leyvraz S., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108 (2006) 3289-3294